delayed onset muscle soreness (pain) M79.62
Conditions
Interventions
Group 1: Preventive blockade of the sympathetic nervous system: immediately prior to the induction of DOMS, volunteers receive the injection of 4-5ml local anaesthetic (procaine) at the stellate gangl
Sponsors
Goethe-Universität Frankfurt
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy subjects, aged 18+ of both gender -Voluntariness -Subjects with the ability to follow study instructions and likely to attend and complete all required visits -Written informed consent
Exclusion criteria
Exclusion criteria: General Exclusion Criteria: -Subjects not able to give consent -Subject without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial -Known history of hypersensitivity to local anesthetics -Simultaneously participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning -Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial - Known or persistent abuse of medication, drugs or alcohol Exclusion criteria regarding special restrictions for females: -Current or planned pregnancy or nursing women Indication specific exclusion criteria: -pain, -neuromuscular disease, -cancer, -diagnosed coagulation disorder, -intake of anti-coagulants, -severe heart failure (NYHA III-IV) or cardiac decompensation, -cardiac conduction defect, i.e. e.g atrioventricular block II-II, -peripheral or central vascular disease, -known paresis of the recurrens or phrenic nerve of the contralateral side, -hperreagible scars or wounds at the non-dominant upper extremity, -regional sensibility disorders, -regional skin transplants at the non-dominant upper extremity, -amputation of upper extremities -chronic intake of analgesic, neuroleptics, antidepressants, corticoids or alpha2-blockers -Paresis of recurrens or phrenical nerve at the contralateral side, -Severe pulmonary emphysema
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pressure pain threshold (over time) when comparing a) Group 1 (preventive) to control OR b) Group 2 (rehabilitative) to control | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints will be compared at 24, 48, 72 and 96 hours. -Pressure Pain Threshold (PPT) -Pain intensity (VAS) -Mechanical Pain Threshold (MPT) -Maximum isovolumetric force MIVF -McGill shortform pain inventory -Skin temperature -Blood samples: molecular serum markers of muscle damage, i.e. e.g. cfDNA | — |
Countries
Germany
Contacts
Public ContactJohannes Fleckenstein
Abteiulung für Sportmedizin,Institut für SportwissenschaftenGoethe-Universität Frankfurt
Outcome results
None listed